Holen Sie sich die Stockscreener-App
1.32
0.00%
0.00
Handel nachbörslich:
1.33
0.01
+0.76%
Schlusskurs vom Vortag:
$1.32
Offen:
$1.32
24-Stunden-Volumen:
1.09M
Relative Volume:
3.78
Marktkapitalisierung:
$56.11M
Einnahmen:
$51.13M
Nettoeinkommen (Verlust:
$-93.80M
KGV:
-8.80
EPS:
-0.15
Netto-Cashflow:
$-129.10M
1W Leistung:
-25.42%
1M Leistung:
-53.52%
6M Leistung:
-62.50%
1J Leistung:
-79.66%
1-Tages-Spanne:
$1.30
$1.45
1-Wochen-Bereich:
$1.225
$1.83
52-Wochen-Spanne:
$1.225
$8.49
Repare Therapeutics Inc Stock (RPTX) Company Profile
Firmenname
Repare Therapeutics Inc
Sektor
Branche
Telefon
(857) 412-7018
Adresse
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Vergleichen Sie RPTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.32 | 56.11M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-09 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-04-12 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-17 | Fortgesetzt | Goldman | Buy |
| 2021-09-23 | Eingeleitet | Stifel | Buy |
| 2021-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-03-01 | Eingeleitet | Berenberg | Buy |
| 2020-10-28 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-14 | Eingeleitet | Cowen | Outperform |
| 2020-07-14 | Eingeleitet | Goldman | Neutral |
| 2020-07-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Repare Therapeutics Inc Aktie (RPTX) Neueste Nachrichten
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World
Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat
LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - Yahoo Finance
Repare Therapeutics stock hits 52-week low at $2.35 - Investing.com
Stifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00 - MarketBeat
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News
Promising trial results for Repare's cancer drug combo - Investing.com India
Repare stock tanks 38% after Phase 1 data release - MSN
Promising trial results for Repare's cancer drug combo By Investing.com - Investing.com UK
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
Repare Therapeutics' Cancer Drug Combo Shows Strong 37.5% Response Rate in Advanced Ovarian Cancer Trial - StockTitan
Press Release Service: Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - BioSpace
UK desirability has turned a corner in clinical trials - Yahoo Finance
Repare Therapeutics to Present Phase 1 Cancer Trial Data for Novel Drug Combination in December - StockTitan
Analysts' Revenue Estimates For Repare Therapeutics Inc. (NASDAQ:RPTX) Are Surging Higher - Simply Wall St
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts - Yahoo Finance
Repare Therapeutics partners with NCI on cancer drug By Investing.com - Investing.com Australia
Press Release Service: Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - CRISPR Medicine News
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib - BioSpace
Repare Therapeutics partners with NCI on cancer drug - Investing.com India
Repare Therapeutics Partners with NCI to Advance Breakthrough Cancer Drug Camonsertib | RPTX Stock News - StockTitan
Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics Reports Q3 2024 Progress and Outlook - TipRanks
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results - CRISPR Medicine News
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint - Yahoo Finance
Repare Therapeutics (NASDAQ:RPTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Repare Therapeutics’ individualised anaemia management trial shows promise - Yahoo Finance
Press Release Service: Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial - BioSpace
Repare Therapeutics reports progress in cancer trial - Investing.com India
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug - MSN
Dimensional Fund Advisors LP Sells 27,504 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) - Defense World
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor - CRISPR Medicine News
Repare Therapeutics doses first subject in Phase I solid tumour trial - Yahoo! Voices
Repare Therapeutics begins trial for novel cancer drug By Investing.com - Investing.com Australia
Finanzdaten der Repare Therapeutics Inc-Aktie (RPTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Repare Therapeutics Inc-Aktie (RPTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Apr 01 '24 |
Sale |
4.63 |
2,491 |
11,533 |
107,558 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Sale |
4.62 |
825 |
3,812 |
45,564 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Sale |
4.61 |
789 |
3,637 |
44,775 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 28 '24 |
Sale |
4.64 |
450 |
2,088 |
72,318 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Apr 01 '24 |
Sale |
4.66 |
410 |
1,911 |
71,908 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER |
Mar 28 '24 |
Sale |
4.64 |
500 |
2,320 |
231,709 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER |
Apr 01 '24 |
Sale |
4.66 |
300 |
1,398 |
231,409 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 25 '24 |
Sale |
4.79 |
825 |
3,952 |
43,862 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 27 '24 |
Sale |
4.62 |
825 |
3,812 |
42,212 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 26 '24 |
Sale |
4.60 |
825 |
3,795 |
43,037 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):